NCT04008680

Brief Summary

This study investigates how reliability of patient reported outcomes can be affected with questionnaire burden and and the number of questionnaires given to study participants.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
110

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started May 2021

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 26, 2019

Completed
9 days until next milestone

First Posted

Study publicly available on registry

July 5, 2019

Completed
1.9 years until next milestone

Study Start

First participant enrolled

May 17, 2021

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 31, 2022

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2022

Completed
Last Updated

July 28, 2021

Status Verified

July 1, 2021

Enrollment Period

1.2 years

First QC Date

June 26, 2019

Last Update Submit

July 26, 2021

Conditions

Keywords

consistencyreliabilityburdenresponsemethodology

Outcome Measures

Primary Outcomes (1)

  • Reliability and validity of the EQ-5D-5L

    The questionnaire selected to analyze reliability in our population is the EQ-5D-5L.This well-known, generic, patient-reported health questionnaire is frequently used in musculoskeletal research and has shown to have a good internal consistency. We will compute the Cronbach's alpha coefficient for the EQ-5D-5L questionnaire. We will contrast these results to analyze if there is any difference in the values obtained from the answers of the EQ-5D-5L questionnaire between the four groups.

    Day 1

Secondary Outcomes (1)

  • Time to completion

    Day 1

Study Arms (4)

Low response burden

OTHER

Participants will be assigned to complete only the EQ-5D-5L questionnaire.

Other: EQ-5D-5L survey internal consistency

Low to medium response burden

OTHER

Participants will be assigned to complete the General Anxiety Disorder-7 (GAD-7) questionnaire first, followed by the EQ-5D-5L questionnaire.

Other: EQ-5D-5L survey internal consistency

Medium to high response burden

OTHER

Participants will be assigned to complete the Pain Catastrophizing Scale (PCS) questionnaire first, followed by the GAD-7, and lastly the EQ-5D-5L questionnaire.

Other: EQ-5D-5L survey internal consistency

High response burden

OTHER

Participants will be assigned to complete the Brief Pain Inventory (BPI) questionnaire first, followed by the PCS secondly, the GAD-7 third, and lastly the EQ-5D-5L questionnaire.

Other: EQ-5D-5L survey internal consistency

Interventions

To see how increasing the number of questionnaires affects the internal consistency of the EQ-5D-5L.

High response burdenLow response burdenLow to medium response burdenMedium to high response burden

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • The patient presents to the in-person or virtual fracture clinic for his/her own appointment.
  • The patient has a fracture that is being managed either operatively or non-operatively.
  • Fracture occurred in the past 6 months.
  • The patient is 18 years of age or older.
  • The patient is able to read, understand, and write in English.
  • Patient provides informed, verbal or written consent.

You may not qualify if:

  • The patient is considered too ill or injured to participate in the study.
  • The patient is cognitively impaired, intoxicated or otherwise unable to provide consent or participate in the study.
  • The patient is co-enrolled in another study requiring completion of multiple additional PROMs.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hamilton Health Sciences - General Site

Hamilton, Ontario, Canada

RECRUITING

Study Officials

  • Francesc Antoni Marcano-Fernandez, PhD

    McMaster University

    PRINCIPAL INVESTIGATOR
  • Herman Johal, MD

    McMaster University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Gina Del Fabbro, BPH

CONTACT

Carlos Prada

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
OTHER
Intervention Model
PARALLEL
Model Details: 4 group randomized clinical trial
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 26, 2019

First Posted

July 5, 2019

Study Start

May 17, 2021

Primary Completion

July 31, 2022

Study Completion

December 31, 2022

Last Updated

July 28, 2021

Record last verified: 2021-07

Data Sharing

IPD Sharing
Will not share

Undecided. Data collected (Internal consistency, demographics etc will be shared previous agreement)

Locations